Precigen, Inc. (NASDAQ: PGEN) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -1.14 | Insider Own | 26.82% | Shs Outstand | 356.51M | Perf Week | 17.81% |
| Market Cap | 2.81B | Forward P/E | 11.52 | EPS next Y | 0.68 | Insider Trans | -6.38% | Shs Float | 159.28M | Perf Month | 16.59% |
| Enterprise Value | 2.86B | PEG | - | EPS next Q | 0.09 | Inst Own | - | Short Float | 11.83% | Perf Quarter | 66.38% |
| Income | -158.00M | P/S | 32.62 | EPS this Y | 112.28% | Inst Trans | - | Short Ratio | 7.80 | Perf Half Y | 140.67% |
| Sales | 86.00M | P/B | 63.78 | EPS next Y | 388.09% | ROA | -92.61% | Short Interest | 42.18M | Perf YTD | 88.28% |
| Book/sh | 0.12 | P/C | 73.83 | EPS next 5Y | 80.62% | ROE | -498.32% | 52W High | 7.95 -1.01% | Perf Year | 102.31% |
| Cash/sh | 0.11 | P/FCF | - | EPS past 3/5Y | - | ROIC | -27.82% | 52W Low | 2.99 163.21% | Perf 3Y | 417.76% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | -28.19% -20.76% | Gross Margin | 89.56% | Volatility | 4.59% 4.40% | Perf 5Y | 26.32% |
| Dividend TTM | - | EV/Sales | 33.31 | EPS Y/Y TTM | -142.55% | Oper. Margin | -46.08% | ATR (14) | 0.35 | Perf 10Y | -70.73% |
| Dividend Ex-Date | - | Quick Ratio | 3.89 | Sales Y/Y TTM | 2050.00% | Profit Margin | -183.98% | RSI (14) | 69.27 | Recom | 2.38 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.58 | EPS Q/Q | 145.45% | SMA20 | 10.81% | Beta | 0.95 | Target Price | 18.00 |
| Payout | 0.00% | Debt/Eq | 4.62 | Sales Q/Q | 5400.00% | SMA50 | 22.37% | Rel Volume | 1.86 | Prev Close | 7.44 |
| Employees | 160 | LT Debt/Eq | 4.62 | Earnings | Nov 12 | SMA200 | 65.11% | Avg Volume | 5.02M | Price | 7.87 |
| IPO Date | Aug 08, 2013 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 779.04% 96.47% | Net Debt/EBITDA | -0.57 | Volume | 9,336,264 | Change | 5.78% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-05-26 | Reiterated | HC Wainwright & Co. | Buy | $14 → $18 |
| Aug-03-26 | Reiterated | HC Wainwright & Co. | Buy | $14 → $18 |
| May-28-26 | Reiterated | HC Wainwright & Co. | Buy | $11 → $14 |
| May-14-26 | Reiterated | HC Wainwright & Co. | Buy | $6.00 → $11 |
| Aug-15-25 | Upgrade | JP Morgan | Underweight → Neutral | |
| Mar-22-24 | Downgrade | JP Morgan | Neutral → Underweight | |
| Aug-09-22 | Reiterated | HC Wainwright & Co. | Buy | $6.00 |
| Mar-01-19 | Downgrade | Northland Securities | Outperform → Perform | |
| Jul-16-18 | Downgrade | Bank of America | Neutral → Underperform | |
| Nov-11-15 | Upgrade | Mizuho | Underperform → Neutral |
Precigen, Inc. is an American company dedicated to the discovery and development of cutting-edge gene and cellular therapies. The company also offers disease-modifying treatments, genetically engineered swine for regenerative medicine, and advanced reproductive and embryo transfer technologies. Its extensive portfolio of proprietary platforms includes UltraVector, which leverages advanced DNA construction and computational modeling to engineer complex gene expression programs; mbIL15, a gene designed to enhance immune cell function; the non-viral Sleeping Beauty transposon/transposase system for genetic modification; and AttSite recombinases, tools for precise DNA recombination. Furthermore, Precigen utilizes its AdenoVerse platform, a library of engineered adenovectors for gene delivery and immunotherapy applications, alongside L. lactis, a food-grade bacterium. The company also provides RheoSwitch, an inducible gene switch system offering quantitative, dose-proportionate control over target protein expression's timing and amount; kill switches, designed to selectively eliminate cell therapies within the body; tissue-specific promoters for targeted gene expression; the UltraCAR-T platform for cancer treatment; and the ActoBiotics platform, which employs genetically modified bacteria to deliver proteins and peptides directly to mucosal sites. Precigen maintains strategic collaboration and license agreements with Alaunos Therapeutics, Inc., Ares Trading S.A., Oragenics, Inc., Castle Creek Biosciences, Inc., and Intrexon Energy Partners I and II, LLC. Established in 1998, Precigen, Inc., previously known as Intrexon Corporation, adopted its current name in January 2020 and is headquartered in Germantown, Maryland.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 86 | 10 | 4 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 9 | 6 | 4 | — | — | — | — | — | — | |
| Gross Profit | 77 | 4 | 0 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 85 | 70 | 41 | — | — | — | — | — | — | |
| Research and Development | 31 | 40 | 53 | — | — | — | — | — | — | |
| Other Operating Expense | 0 | 0 | 41 | — | — | — | — | — | — | |
| Operating Income | -39 | -107 | -135 | — | — | — | — | — | — | |
| Interest Expense | 10 | 4 | 0 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -109 | -140 | 7 | — | — | — | — | — | — | |
| Net Income Before Taxes | -158 | -251 | -128 | — | — | — | — | — | — | |
| Income Taxes | 0 | 0 | -2 | — | — | — | — | — | — | |
| Consolidated Net Income | -158 | -251 | -126 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -158 | -251 | -126 | — | — | — | — | — | — | |
| Net Income | -158 | -251 | -126 | — | — | — | — | — | — | |
| EPS (Recurring) | -1.13 | -1.41 | -0.47 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -1.13 | -1.41 | -0.47 | — | — | — | — | — | — | |
| EPS (Diluted) | -1.14 | -1.41 | -0.47 | — | — | — | — | — | — | |
| EBITDA | -145 | -244 | -123 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 32.67 | 127.49 | 75.04 | — | — | — | — | — | — | |
| Gross Margin | 89.53 | 40.00 | 0.00 | — | — | — | — | — | — | |
| Operating Margin | -45.35 | -1,070.00 | -3,375.00 | — | — | — | — | — | — | |
| Net Margin | -183.72 | -2,510.00 | -3,150.00 | — | — | — | — | — | — | |
| Shares Outstanding | 357 | 305 | 268 | — | — | — | — | — | — | |
| Market Capitalization | 2,810 | 1,275 | 300 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| KINDLER JEFFREY B | Director | Aug 26 '26 | Sale | 7.44 | 185,000 | 1,376,400 | 17,100 | Aug 28 |
| Shah Rutul R | Chief Operating Officer | Aug 25 '26 | Option Exercise | 2.33 | 15,342 | 35,747 | 484,207 | Aug 25 |
| Tennant Phil | Chief Commercial Officer | Aug 25 '26 | Option Exercise | 1.61 | 79,166 | 127,457 | 221,158 | Aug 25 |
| Shah Rutul R | Chief Operating Officer | Aug 25 '26 | Sale | 7.50 | 15,342 | 115,065 | 468,865 | Aug 25 |
| Tennant Phil | Chief Commercial Officer | Aug 25 '26 | Sale | 7.50 | 79,166 | 593,745 | 141,992 | Aug 25 |
| Lehr Donald P. | Chief Legal Officer | Aug 23 '26 | Option Exercise | 0.00 | 5,208 | 0 | 760,669 | Aug 25 |
| Tennant Phil | Chief Commercial Officer | Aug 23 '26 | Option Exercise | 0.00 | 5,208 | 0 | 144,577 | Aug 25 |
| Sabzevari Helen | President and CEO | Aug 23 '26 | Option Exercise | 0.00 | 20,833 | 0 | 3,789,705 | Aug 25 |
| Thomasian Harry Jr. | Chief Financial Officer | Aug 23 '26 | Option Exercise | 0.00 | 7,291 | 0 | 261,826 | Aug 25 |
| Shah Rutul R | Chief Operating Officer | Aug 23 '26 | Option Exercise | 0.00 | 7,500 | 0 | 472,512 | Aug 25 |
| AGEE NANCY H | Director | Aug 21 '26 | Buy | 7.23 | 3,411 | 24,662 | 309,187 | Aug 25 |
| Shah Rutul R | Chief Operating Officer | Aug 21 '26 | Option Exercise | 2.33 | 34,658 | 80,753 | 499,670 | Aug 25 |
| Shah Rutul R | Chief Operating Officer | Aug 21 '26 | Sale | 7.50 | 34,658 | 259,935 | 465,012 | Aug 25 |
| Shah Rutul R | Chief Operating Officer | Aug 06 '26 | Sale | 6.86 | 32,739 | 224,590 | 465,012 | Aug 07 |
| Shah Rutul R | Chief Operating Officer | Aug 03 '26 | Option Exercise | 2.33 | 33,772 | 78,689 | 531,523 | Aug 03 |